Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes

British Journal of Haematology

Volumn 159, Issue 3, 2012, Pages 311-321

  Saumell, Sílvia ^a,b   Florensa, Lourdes ^a   Luño, Elisa ^c   Sanzo, Carmen ^c   Cañizo, Consuelo ^d   Hernández, Jesus M ^d   Cervera, José ^e   Gallart, Miguel A ^f   Carbonell, Félix ^g   Collado, Rosa ^g   Arenillas, Leonor ^a   Pedro, Carme ^a   Bargay, Joan ^h   Nomdedeu, Benet ⁱ   Xicoy, Blanca ^j   Vallespí, Teresa ^k   Raya, José M ^l   Belloch, Luis ^e   Sanz, Guillermo F ^e   Solé, Francesc ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h HOSPITAL SON LLÀTZER   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

more..

Author keywords

Cytogenetic aberrations; Myelodysplastic syndromes; Trisomy 8

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; GENETIC RISK; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SURVIVAL RATE; SYNDROME DELINEATION; THROMBOCYTE COUNT; TRISOMY 8;

ADULT; AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 8; DISEASE PROGRESSION; FEMALE; HUMANS; KARYOTYPE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK; TRISOMY;

EID: 84867447235     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12035     Document Type: Article

References (31)

1. Bernasconi, P., Klersy, C., Boni, M., Cavigliano, P.M., Calatroni, S., Giardini, I., Rocca, B., Zappatore, R., Caresana, M., Dambruoso, I., Lazzarino, M. & Bernasconi, C. (2007) World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. British Journal of Haematology, 137, 193-205.
2. Brunning, R.D., Bennett, J., Flandrin, G., Matutes, E., Head, D., Vardiman, J.W. & Harris, N.L. (2001) Myelodysplastic syndromes. In: Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe, N.L. Harris, H. Stein & J.W. Vardiman), pp. 61-73. IARC, Lyon.
3. Brunning, R.D., Orazi, A., Germing, U., Le Beau, M.M., Porwit, A. & Baumann, I. (2008) Myelodysplastic syndromes. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed. by S.H. Swerdlow, E. Campo, N. Lee Harris, E.S. Jaffe, S.A. Pieri & H. Stein), pp. 87-107. IARC, Lyon.
4. Chun, K., Hagemeijer, A., Iqbal, A. & Slovak, M.L. (2010) Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: an International Working Group on MDS Cytogenetics Study. Leukemia Research, 34, 160-165.
5. Cox, D.R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society. Series B, Statistical Methodology, 34, 187-220.
6. Gonzalez-Porras, J.R., Cordoba, I., Such, E., Nomdedeu, B., Vallespi, T., Carbonell, F., Luno, E., Ardanaz, M., Ramos, F., Pedro, C., Gomez, V., de Paz, R., Sanchez-Barba, M., Sanz, G.F. & Del Canizo, A.C. (2011) Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer, 117, 5529-5537.
7. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
8. Haase, D., Germing, U., Schanz, J., Pfeilstocker, M., Nosslinger, T., Hildebrandt, B., Kundgen, A., Lubbert, M., Kunzmann, R., Giagounidis, A.A., Aul, C., Trumper, L., Krieger, O., Stauder, R., Muller, T.H., Wimazal, F., Valent, P., Fonatsch, C. & Steidl, C. (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood, 110, 4385-4395.
9. Kantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J.M., List, A., Fenaux, P., Sanz, G., Issa, J.P., Freireich, E.J. & Garcia-Manero, G. (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer, 113, 1351-1361.
10. Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
11. Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M.G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., Strupp, C., Lazzarino, M., Aul, C. & Cazzola, M. (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of Clinical Oncology, 25, 3503-3510.
12. Mallo, M., Luno, E., Sanzo, C., Cervera, J., Haase, D., Schanz, J., Garcia-Manero, G., del Canizo, C., Sanz, G.F. & Sole, F. (2011) Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leukemia Research, 35, 834-836.
13. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163-170.
14. Mitelman, F., Johansson, B. & Mertens, F.E. (2011) Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
15. Morel, P., Hebbar, M., Lai, J.L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F. & Fenaux, P. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7, 1315-1323.
16. Nowell, P.C. & Besa, E.C. (1989) Prognostic significance of single chromosome abnormalities in preleukemic states. Cancer Genetics and Cytogenetics, 42, 1-7.
17. Paulsson, K. & Johansson, B. (2007) Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. Pathologie Biologie, 55, 37-48.
18. Paulsson, K., Sall, T., Fioretos, T., Mitelman, F. & Johansson, B. (2001) The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genetics and Cytogenetics, 130, 160-165.
19. Pedersen, B. (1997) MDS and AML with trisomy 8 as the sole chromosome aberration show different sex ratios and prognostic profiles: a study of 115 published cases. American Journal of Hematology, 56, 224-229.
20. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1976) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. British Journal of Cancer, 34, 585-612.
21. Pozdnyakova, O., Miron, P.M., Tang, G., Walter, O., Raza, A., Woda, B. & Wang, S.A. (2008) Cytogenetic abnormalities in a series of 1, 029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer, 113, 3331-3340.
22. Schanz, J., Steidl, C., Fonatsch, C., Pfeilstocker, M., Nosslinger, T., Tuechler, H., Valent, P., Hildebrandt, B., Giagounidis, A., Aul, C., Lubbert, M., Stauder, R., Krieger, O., Garcia-Manero, G., Kantarjian, H., Germing, U., Haase, D. & Estey, E. (2011) Coalesced multicentric analysis of 2, 351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. Journal of Clinical Oncology, 29, 1963-1970.
23. Schanz, J., Tuchler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M.L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstocker, M., Nosslinger, T., Valent, P., Giagounidis, A., Aul, C., Lubbert, M., Stauder, R., Krieger, O., Garcia-Manero, G., Faderl, S., Pierce, S., Le Beau, M.M., Bennett, J.M., Greenberg, P., Germing, U. & Haase, D. (2012) New comprehensive cytogenetic scoring system for primary Myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. Journal of Clinical Oncology, 30, 820-829.
24. Shaffer, L.G., Slovak, M.L. & Campbell, L.J. (2009) ISCN 2009: An International System for Human Cytogenetic Nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S. Karger AG, Basel, Switzerland.
25. Sole, F., Prieto, F., Badia, L., Woessner, S., Florensa, L., Caballin, M.R., Coll, M.D., Besses, C. & Sans-Sabrafen, J. (1992) Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genetics and Cytogenetics, 64, 12-20.
26. Sole, F., Espinet, B., Sanz, G.F., Cervera, J., Calasanz, M.J., Luno, E., Prieto, F., Granada, I., Hernandez, J.M., Cigudosa, J.C., Diez, J.L., Bureo, E., Marques, M.L., Arranz, E., Rios, R., Martinez Climent, J.A., Vallespi, T., Florensa, L. & Woessner, S. (2000) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. British Journal of Haematology, 108, 346-356.
27. Sole, F., Luno, E., Sanzo, C., Espinet, B., Sanz, G.F., Cervera, J., Calasanz, M.J., Cigudosa, J.C., Milla, F., Ribera, J.M., Bureo, E., Marquez, M.L., Arranz, E. & Florensa, L. (2005) Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica, 90, 1168-1178.
28. Tefferi, A. & Vardiman, J.W. (2009) Myelodysplastic syndromes. New England Journal of Medicine, 361, 1872-1885.
29. Toyama, K., Ohyashiki, K., Yoshida, Y., Abe, T., Asano, S., Hirai, H., Hirashima, K., Hotta, T., Kuramoto, A., Kuriya, S., Miyazaki, T., Kakishita, E., Mizoguchi, H., Okada, M., Shirakawa, S., Takaku, F., Tomonaga, M., Uchino, H., Yasunaga, K. & Nomura, T. (1993) Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia, 7, 499-508.
30. Valent, P., Horny, H.P., Bennett, J.M., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H.J., Krieger, O., Loken, M., van de, L.A., Ogata, K., Orfao, A., Pfeilstocker, M., Ruter, B., Sperr, W.R., Stauder, R. & Wells, D.A. (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leukemia Research, 31, 727-736.
31. Yunis, J.J., Lobell, M., Arnesen, M.A., Oken, M.M., Mayer, M.G., Rydell, R.E. & Brunning, R.D. (1988) Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. British Journal of Haematology, 68, 189-194.